Full Text Journal Articles by
Author Hana Florian

Advertisement

Find full text journal articles








Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, ,

<h4>Background</h4>Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.<h4>Methods</h4>We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):182-192]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.

Hana Florian, Andreas Meier, Serge Gauthier, Stanley Lipschitz, Yunzhi Lin, Qi Tang, Ahmed A Othman, Weining Z Robieson, Laura M Gault,

<h4>Background</h4>ABT-126 is a potent, selective α7 nicotinic acetylcholine receptor agonist with putative procognitive effects as a monotherapy in treating Alzheimer's disease (AD).<h4>Objective</h4>This randomized, double-blind, placebo-controlled multicenter study (NCT01549834) investigated the efficacy and safety of ABT-126 in subjects with mild-to-moderate AD who were taking stable doses of acetylcholinesterase inhibitors (AChEIs).<h4>Methods</h4>Subjects received ... Read more >>

J Alzheimers Dis (Journal of Alzheimer's disease : JAD)
[2016, 51(4):1237-1247]

Cited: 10 times

View full text PDF listing >>



Advertisement

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Ahmed A Othman, George Haig, Hana Florian, Charles Locke, Lev Gertsik, Sandeep Dutta,

<h4>Aims</h4>ABT-288 is a potent and selective H3 receptor antagonist with procognitive effects in several preclinical models. In previous studies, 3 mg once daily was the maximal tolerated dose in healthy volunteers. This study characterized the safety, tolerability and pharmacokinetics of ABT-288 in stable subjects with schizophrenia.<h4>Methods</h4>This was a randomized, double-blind, ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2014, 77(6):965-974]

Cited: 2 times

View full text PDF listing >>



Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.

Ahmed A Othman, George Haig, Hana Florian, Charles Locke, Jun Zhang, Sandeep Dutta,

<h4>Aim</h4>The objective of this work was to characterize the safety, tolerability and pharmacokinetics of ABT-288, a highly selective histamine H3 receptor antagonist, in healthy young adults and elderly subjects following single and multiple dosing in a phase 1 setting.<h4>Methods</h4>Single doses (0.1, 0.3, 1, 3, 10, 20 and 40 mg ABT-288) and ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2013, 75(5):1299-1311]

Cited: 9 times

View full text PDF listing >>



A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.

Philip J Mease, I Jon Russell, Lesley M Arnold, Hana Florian, James P Young, Susan A Martin, Uma Sharma,

<h4>Objective</h4>To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM.<h4>Methods</h4>This multicenter, double-blind, placebo-controlled trial randomly assigned 748 patients with FM to receive placebo or pregabalin 300, 450, or 600 mg/day (dosed twice daily) for 13 weeks. The primary ... Read more >>

J Rheumatol (The Journal of rheumatology)
[2008, 35(3):502-514]

Cited: 140 times

View full text PDF listing >>





Advertisement

Disclaimer
0.6259 s